Association between the body mass index and risk of cardiovascular events in sodium‐glucose cotransporter 2 inhibitor users compared with dipeptidyl‐peptidase 4 inhibitor users: A nationwide cohort study in Korea

Ähnliche Einträge

• Comparison of renal prognosis between dipeptidyl peptidase‐4 inhibitor users and non‐users
  von: Hideaki Hashimoto, et al.
  Veröffentlicht: (2024)
• Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction‐associated steatotic liver disease: A retrospective nationwide claims database study in Japan
  von: Mitsuhiro Shikamura, et al.
  Veröffentlicht: (2024)
• Risk of insulin initiation with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: A real‐world claims database study in Japan
  von: Ryo Suzuki, et al.
  Veröffentlicht: (2025)
• Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study
  von: Hsiao‐Ling Chen, et al.
  Veröffentlicht: (2024)
• Use of sodium‐glucose cotransporter‐2 inhibitors in France: Analysis of French nationwide health insurance database
  von: Sibylle de Germay, et al.
  Veröffentlicht: (2024)